论文部分内容阅读
腹腔内化疗（ＩＰＣ）是近年提出的一种治疗腹腔内肿瘤的新途径，优点在于全身毒性反应小，对局部肿瘤接触浓度高。但ＩＰＣ仍有许多问题尚未解决。笔者采用４０只小白鼠动物实验，用不同剂量阿霉素作腹腔内注射，观察小白鼠生存率及腹腔内脏器的组织学改变。结果提示加倍量组即（ＤＤＡ）１０／１０于注后２４小时死亡，常量组（ＳＤＡ）２／１０于注后２４小时死亡，８／１０于注后４８小时死亡，减量组（ＬＤＡ）４／１０于注后４８小时死亡，４／１０于注后７２小时死亡。组织学改变为受累组织细胞浊肿→出血→坏死。与ＩＰＣ注射浓度及时间有关。笔者提出阿霉素作为ＩＰＣ的一种抗癌剂可行性差；且指出虽然ＩＰＣ在实验及临床中已被首肯，但选择合适的抗癌剂是十分重要的。
Intraperitoneal chemotherapy (IPC) is a new approach proposed in recent years for the treatment of intraperitoneal tumors, the advantage of systemic toxicity is small, high concentrations of local tumor exposure. However, there are still many problems that remain unresolved. I used 40 mice in animal experiments, with different doses of doxorubicin for intraperitoneal injection, observe the survival rate of mice and intra-abdominal organs of the histological changes. The results suggest that doubly fed group (DDA) 10/10 died 24 hours after the injection, 2/10 of the SDA group died 24 hours after the injection, and 8/10 died 48 hours after the injection. The LDA, 4/10 died 48 hours after injection and 4/10 died 72 hours after injection. Histological changes to the affected cells cloudy → bleeding → necrosis. And IPC injection concentration and time related. The authors suggest that adriamycin as an IPC anti-cancer agent is poorly practicable; and pointed out that although the IPC has been approved in experiments and clinics, but the choice of appropriate anticancer agent is very important.